Patent US4426446A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4426446A Expired / Lapsed US ⏱️ 0.0 years remaining

Leucocyte adherence inhibition assay for detection of cancer

Assignee: Hoffmann La Roche Inc
•
Filing: 1981-02-03
•
Granted: 1984-01-17
•
Expires: 2001-02-03
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods for carrying the leucocyte adherence inhibition (LAI) assay for detecting the presence of cancer in responsive patients. One aspect of the invention utilizes incubation with agents which maximize the intracellular cycle 3',5'-adenosine monophosphate (cAMP) levels in the leucocytes as a means to expand the percentage of responding subjects in different cancers. A second aspect utilizes measurement of extracted, vital cell dye to avoid the need of counting the adhering or non-adhering leucocytes.

Inventors

  • 👤 David M. P. Thomson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-10 01:52
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; G01N33/88; Y; Y10; Y10S; Y10S435/00; Y10S435/962; Y10S436/00; Y10S436/80; Y10S436/811; Y10S436/813

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 189 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocyte are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the test tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises: (a) preincubating said peripheral blood leucocytes with an effective concentration of an agent which maximizes cAMP levels in leucocytes to thereby heighten the LAI response of such leucocytes; and (b) treating said adherent or non-adherent cells with a vital cell dye selected from the group consisting of methylene blue, nonspecific esterase and neutral red, separating said adherent or non-adherent cells, extracting said dye, determining the optical adsorption of said extracted solution which is directly proportional to the number of cells present thus providing the number of adhering or non-adhering cells without the necessity of optically counting such cell directly wherein said agent which maximizes cAMP levels in the leucocytes is a prostaglandin compound which stimulates leucocyte cAMP or a phosphodiesterase inhibitor which prevents cAMP destruction.
Claim 2
Dependent Claim 189 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocyte are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the test tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises: (a) preincubating said peripheral blood leucocytes with an effective concentration of an agent which maximizes cAMP levels in leucocytes to thereby heighten the LAI response of such leucocytes; and (b) treating said adherent or non-adherent cells with a vital cell dye selected from the group consisting of methylene blue, nonspecific esterase and neutral red, separating said adherent or non-adherent cells, extracting said dye, determining the optical adsorption of said extracted solution which is directly proportional to the number of cells present thus providing the number of adhering or non-adhering cells without the necessity of optically counting such cell directly wherein said agent which maximizes cAMP levels in the leucocytes is a prostaglandin compound which stimulates leucocyte cAMP or a phosphodiesterase inhibitor which prevents cAMP destruction.
Claim 3
Dependent Claim 116 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocytes are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises preincubating said peripheral blood leucocytes with an effective concentration of an agent which maximizes cAMP levels in leucocytes to thereby heighten the LAI response of such leucocytes wherein said agent which maximizes cAMP levels in the leucocytes is a prostaglandin compound which stimulates leucocyte cAMP or a phosphodiesterase inhibitor which prevents cAMP destruction.
Claim 4
Dependent Claim 116 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocytes are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises preincubating said peripheral blood leucocytes with an effective concentration of an agent which maximizes cAMP levels in leucocytes to thereby heighten the LAI response of such leucocytes wherein said agent which maximizes cAMP levels in the leucocytes is a prostaglandin compound which stimulates leucocyte cAMP or a phosphodiesterase inhibitor which prevents cAMP destruction.
Claim 5
Dependent Claim 132 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocytes are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises treating said adherent or non-adherent cells with a vital cell dye selected from the group consisting of methylene blue, nonspecific esterase and neutral red, separating said adherent or non-adherent cells, extracting said dye, determining the optical absorption of said extracted solution which is directly proportional to the number of cells present thereby providing the number of adhering or non-adhering cells without the necessity of optically counting such cells directly.
Claim 6
Dependent Claim 132 words
In a tube leucocyte adherence inhibition assay for the detection of cancer in a subject wherein samples of a known amount of peripheral blood leucocytes are incubated horizontally with either specific or nonspecific tumor antigen extracts in test tubes, the tubes are carefully placed vertically and the non-adherent cells are counted for each sample and the non-adherent index determined, the improvement which comprises treating said adherent or non-adherent cells with a vital cell dye selected from the group consisting of methylene blue, nonspecific esterase and neutral red, separating said adherent or non-adherent cells, extracting said dye, determining the optical absorption of said extracted solution which is directly proportional to the number of cells present thereby providing the number of adhering or non-adhering cells without the necessity of optically counting such cells directly.
Claim 7
Dependent Claim 37 words
The leucocyte adherence inhibition assay of claims 1, 2 or 3 wherein the specific antigen is derived from a member selected from the group consisting of a breast, lung, stomach, pancreas, colon, prostate, bladder and melanoma cancer.
Claim 8
Dependent Claim 35 words
The leucocyte adherence inhibition assay of claim 1 or 2 wherein said prostaglandin is prostaglandin E 2 present in the preincubation medium in a molar concentration of between about 10 -5 to 10 -6 .
Claim 9
Dependent Claim 30 words
The leucocytes adherence inhibition assay of claim 5 wherein said prostaglandin is prostaglandin E 2 present in combination with aminophyllin both at a molar concentration of about 10 -5 .
Claim 10
Dependent Claim 17 words
The leucocyte adherence inhibition assay of claim 1 or 2 wherein said prostaglandin is nat. 11R-methyl-16R-fluoro-15R-hydroxy-9S-hydroxyprosta-cis-6-trans-13-dienoic acid.
Claim 11
Dependent Claim 19 words
The leucocyte adherence inhibition assay of claim 1 or 2 wherein said agent is a substituted benzylimidazolidione phosphodiesterase inhibitor.
Claim 12
Dependent Claim 13 words
The leucocyte adherence inhibition assay of claim 8 wherein said agent is d,l-4-(3-isopropoxy-4-methoxybenzyl)-2-imidazolidinone.
Claim 13
Dependent Claim 18 words
The leucocyte adherence inhibition assay of claims 1 or 3 wherein said vital cell dye is methylene blue.
Claim 14
Dependent Claim 19 words
The leucocyte adherence inhibition assay of claim 10 wherein said vital cell dye is extracted with dilute hydrochloric acid.
Claim 15
Dependent Claim 18 words
The leukocyte adherence inhibition assay of claim 1 or 2 wherein said prostaglandin is nat. 11R-methyl-16R fluoro-9,15-dioxoprosta-cis-5-trans-13-dienoic acid.

References Cited (Backward Citations)

US4094745A Cited
US4060457A Cited
US3999944A Cited
US4254219A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-01-16 1987-07-18 1988-01-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-01-16 1991-07-18 1992-01-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-01-16 1995-07-18 1996-01-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag